Aktuellt
SENASTE
Redeye is encouraged to learn that Lipum’s lead candidate, SOL-116, has shown favorable safety and tolerability in the first part of the phase 1 study (SAD). Furthermore, the data confirm a preferred pharmacokinetic profile and that SOL-116 interacts with its target protein BSSL in treated subjects. We emphasize that the results are positive for the company and argue that they warrant a positive share price reaction.
LÄS MER
